Allogene Therapeutics (ALLO) Retained Earnings (2019 - 2025)
Allogene Therapeutics (ALLO) has disclosed Retained Earnings for 7 consecutive years, with -$2.0 billion as the latest value for Q4 2025.
- Quarterly Retained Earnings fell 10.49% to -$2.0 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$2.0 billion through Dec 2025, down 10.49% year-over-year, with the annual reading at -$2.0 billion for FY2025, 10.49% down from the prior year.
- Retained Earnings hit -$2.0 billion in Q4 2025 for Allogene Therapeutics, down from $235000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $235000.0 in Q3 2025 to a low of -$2.0 billion in Q4 2025.
- Historically, Retained Earnings has averaged -$706.3 million across 5 years, with a median of -$346.2 million in 2021.
- Biggest YoY gain for Retained Earnings was 106.51% in 2024; the steepest drop was 190457.38% in 2024.
- Year by year, Retained Earnings stood at -$894.6 million in 2021, then tumbled by 38.05% to -$1.2 billion in 2022, then skyrocketed by 99.92% to -$955000.0 in 2023, then crashed by 190457.38% to -$1.8 billion in 2024, then dropped by 10.49% to -$2.0 billion in 2025.
- Business Quant data shows Retained Earnings for ALLO at -$2.0 billion in Q4 2025, $235000.0 in Q3 2025, and -$45000.0 in Q2 2025.